Pharmacogenomics to Address Adverse Drug Events
Washington Convention Center, Room 143A/B
3:00 pm – 5:30 pm
Sponsored by the Divisions for Toxicology; Drug Discovery, Development & Regulatory Affairs; and Integrative Systems, Translational & Clinical Pharmacology
Chairs: D.L. Mendrick, NCTR/FDA and P.B. Watkins, Hamner Institue for Health Sci.
Complexity in the analysis of pharmacogenomic data
Donna L. Mendrick, National Ctr for Toxicology Research/FDA
The application of pharmacogenomics into genetic toxicity and carcinogenicity testing
Jiri Aubrecht, Pfizer Global Research and Development
Exploring the impact of SNPs of idiosyncratic hepatotoxicity
Paul B. Watkins, The Hamner Institute for Health Safety Sciences
A risk/benefit view of safety pharmacogenomics
Issam Zineh, Ctr for Drug Evaluation and Research/FDA
Physiology and Pharmacology of Trace Amine Associated Receptors
Washington Convention Center, Room 143C
3:00 pm – 5:30 pm
Sponsored by the Divisions for Neuropharmacology and Molecular Pharmacology; Behavioral Pharmacology; and Integrative Systems, Translational & Clinical Pharmacology
Chair: R.R. Gainetdinov, Italian Inst. of Technology, Italy and K.A. Neve, VA Med Ctr, Oregon Hlth Sci. Univ.
Trace amine-associated receptor 1 (TAAR1) pharmacology and modulation of brain dopaminergic activity
Marius C. Hoener, F. Hoffman-La Roche, Ltd.
TAARs
and odor-driven behaviors
Stephen D. Liberles, Harvard Medical School
Structure-activity relationships and species selectivity of TAAR1 ligands
Anita H. Lewin, RTI International
Trace amine-associated receptor 1 (TAAR1) as an emerging therapeutic target
Raul R. Gainetdinov, Italian Institute of Technology
Recent Developments in the Understanding of the Biology and Physiology of the JAK Family of Tyrosine Kinases
Washington Convention Center, Room 140A
3:00 pm – 5:30 pm
Sponsored by the Divisions for Drug Discovery, Development & Regulatory Affairs; Drug Metabolism; Integrative Systems, Translational & Clinical Pharmacology; and Molecular Pharmacology
Chair: M.A. Sills, AD4 Pharma
Janus kinases: role in
cytokine signaling and as therapeutic targets
John O’Shea, NIAMS,
NIH
JAK inhibitors as novel
anti-inflammatory agents
James D. Clark, Pfizer
The emerging role of Jak1/Jak2 kinases in solid
tumors
Michael Zinda, AstraZeneca
JAK1/JAK2 inhibition in myeloproliferative
neoplasms and beyond
Jordan Fridman, Incyte Corporation
Therapeutic Angiogenesis
Washington Convention Center, Room 141
3:00 pm – 5:30 pm
Sponsored by the Divisions for Cardiovascular Pharmacology; Drug Discovery, Development & Regulatory Affairs; and Integrative Systems, Translational & Clinical Pharmacology
Chairs: S. Sengupta, Harvard-MIT Brigham and Women’s Hosp. and R. Sinha Roy, Harvard-MIT
Brigham and Women’s Hosp.
Adult stem cell therapy for ischemic tissue repair
A. Mackie, Feinberg Cardiovascular Research Institute, Northwestern Univ
Stem cells and cardiomyogenesis
A. Leri, Dana-Farber/Harvard Cancer Center
Engineering biomaterials to control local cellular
microenvironments toward therapy development
J. Burdick, Univ. of Pennsylvania
Integrating
protein engineering and nanotechnology for therapeutic angiogenesis
R. Sinha Roy, Harvard Med. Sch., Brigham and Women’s Hosp
Therapeutic cardiac angiogenesis and myogenesis:
The promises and challenges on a new frontier
R.C.J. Chiu, McGill Univ. Faculty of Med., Canada
Festschrift Symposium Celebrating More than Three Decades of Mentorship by Dr. Paul Insel
Washington Convention Center, Room 140B
1:00 pm - 5:00 pm
Session I - Chairs: K. Meier, Washington State University and J.R. Jasper, Cytokinetics, Inc.
Welcome
Kathryn Meier, Washington State Univ
The uninsulated Insel: A capsule of Paul in Pharmacology at UCSD
Palmer Taylor, UCSD
Targeting cAMP in chronic lymphocytic leukemia: A pathway-dependent approach
Fiona Murray, UCSD
ß3-Adrenoceptors as drug targets
Martin Michel, Univ of Amsterdam
Genetic polymorphisms and prediction of disease progression: A pediatrician's (critical) view
Rainer Büscher, University Children's Hospital, Essen
Break
Session II Chairs: H. Motulsky, GraphPad Software, Inc. and M.C. Michel, University of Amsterdam
Molecular mechanisms of autonomic neuron development
Marthe Howard, Univ of Toledo
A novel therapeutic strategy for glioma based on clinicopathological analysis
Hirohishi Nishihara, Hokkaido Univ, Sapporo
New medicines for diseases of the aging population
R. McKernan, Pfizer Global Research and Development, Sandwich
Paul's Halcyon Days!
Henry Bourne, UCSF
Closing remarks: The PI factor
Harvey Motulskyk, GraphPad Software, Inc.
Register here for the dinner honoring Paul Insel.
RGS/AGS Proteins in the Visual and Cardiovascular Systems
Washington Convention Center, Room TBD
2:00 pm - 5:00 pm
Sponsored by the Divisions for Molecular Pharmacology and Neuropharmacology
Chairs: J. R. Hepler, Emory Univ and V. Zachariou, University of Crete, Greece
Note: This session is part of a colloquium on RGS/AGS Proteins in Physiology and Disease which continues Wednesday evening and Thursday morning. While this session on the visual and cardiovascular systems is open to any EB registrant, attendance at the poster sessions, dinner and remainder of the colloquium Wednesday evening and Thursday requires separate registration.
R7 RGS regulation of
Class A and Class C GPCR Pathways
T. Wensel, Baylor College of Medicine
Visual system: AGS/PcP2/Go signaling in retina
N. Vardi, Univ of Pennsylvania
Inflammation and cardiovascular disease: RGS in bronchial smooth muscle/asthma
K. Druey, NIAID/NIH
Inflammation and cardiovascular disease: RGS modulation of myocyte stress responses in heart disease
David Kass, Johns Hopkins Univ
Inflammation and cardiovascular disease: RGS proteins in cardiovascular function
Scott Heximer, Univ of Toronto
For the remainder of the RGS/AGS Proteins in Physiology and Disease Program, click HERE